


PHARMACEUTICAL 2020

MEI Pharma Inc. Rank 94 of 362







PHARMACEUTICAL 2020

MEI Pharma Inc. Rank 94 of 362



The relative strengths and weaknesses of MEI Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MEI Pharma Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 206% points. The greatest weakness of MEI Pharma Inc. is the variable Revenues, reducing the Economic Capital Ratio by 68% points.

The company's Economic Capital Ratio, given in the ranking table, is -27%, being 276% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	82,198
Cost of Goods Sold	4,263
Intangible Assets	261
Liabilities, Current	14,301
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	1.0
Other Liabilities	20,432
Other Net Income	29,427
Property and Equipment	204
Research and Development	32,300
Revenues	4,915
Selling, General and Administrative Expense	14,597

Output Variable	Value in 1000 USD
Assets	82,663
Liabilities	34,733
Expenses	51,161
Stockholders Equity	47,930
Net Income	-16,819
Comprehensive Net Income	-16,819
Economic Capital Ratio	-27%